Skip to content
Peptigraph home

Semaglutide

GLP-1 agonist. Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus); research-chemical versions are not the approved drug.

Also called:semaOzempicWegovyRybelsusWegovy pill
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusFDA approved (Ozempic, Wegovy, Rybelsus)Not on the WADA Prohibited ListFull legal history

Key facts

Class
GLP-1 agonist
Also called
sema, Ozempic
Vial sizes sold
2 mg, 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg
Community-reported sizes
Half-life
approximately 1 week
subcutaneous, in people · FDA label (Ozempic)
FDA status
Approved (Ozempic, Wegovy, Rybelsus)
Approved
WADA
Not listed
2026 Prohibited List
Everything on Semaglutide

Semaglutide guides

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

Semaglutide: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Weight loss1,97816014Human RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 40934115
Diabetes1,9861395Human RCT evidence, 4 of 4The New England journal of medicine 2024, PMID 38785209
EnergyNot in our ledgerNot in our ledger0No graded study for this goal
Muscle growthNot in our ledgerNot in our ledger1No graded study for this goal
Kidney diseaseNot in our ledgerNot in our ledger2Human RCT evidence, 4 of 4Nature medicine 2025, PMID 39455729
Liver health305592Human RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 40305708
DepressionNot in our ledgerNot in our ledger2Human observational evidence, 3 of 4EClinicalMedicine 2024, PMID 39764175
Joint painNot in our ledgerNot in our ledger1Human RCT evidence, 4 of 4The New England journal of medicine 2024, PMID 39476339
CognitionNot in our ledgerNot in our ledger3Human RCT evidence, 4 of 4Lancet 2026, PMID 41865758
Inflammation502Human RCT evidence, 4 of 4American heart journal 2025, PMID 40345413
ADHDNot in our ledgerNot in our ledger0No graded study for this goal
Heart health906388Human RCT evidence, 4 of 4American heart journal 2025, PMID 40345413
EyesNot in our ledgerNot in our ledger0No graded study for this goal
Gut healthNot in our ledgerNot in our ledger0No graded study for this goal
WomenNot in our ledgerNot in our ledger0No graded study for this goal

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

Semaglutide in one paragraph

Semaglutide is sold under separate brand names for diabetes and for weight management. The Wegovy label calls it a GLP-1 receptor agonist.[26]

The Ozempic label gives an elimination half-life of approximately 1 week.[14]

Strongest finding and the unresolved question

In STEP 1, mean body-weight change was -14.9% on semaglutide against -2.4% on placebo.[27]

In the SELECT trial of adults with obesity and no diabetes, a primary cardiovascular event occurred in 6.5% on semaglutide against 8.0% on placebo (hazard ratio 0.80).[28]

Body composition is an open question: a systematic review found lean mass made up from almost 0% to 40% of the weight lost across trials.[29]

Observational data on mood disagree, and none of it is randomized. One cohort reported a 195% higher risk of major depression among people on GLP-1 drugs.[30]

A different cohort, in type 2 diabetes, found no higher 12-month risk of adverse neuropsychiatric outcomes than with other diabetes drugs.[10]

Regulatory path

Drugs@FDA lists semaglutide as a prescription product; the cached record shows the tablet form with an original approval date of 20190920.[2]

In the EU the centrally authorised list includes Wegovy with status Authorised.[31]

WADA's S0 catch-all applies only to substances with no government approval, so approved semaglutide is outside it.[1]

Compared with

Common stacks

Semaglutide is often sold pre-mixed or combined with other peptides. A few of these pairs appear together in published studies; each stack page lists what was tested, and the pages below cover the math and what each part has been studied for.

Common questions

Is Semaglutide FDA approved?

Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Products sold as research chemicals are not the approved drug and are not checked by the FDA.

How much water goes in a 10 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

What is semaglutide?

A GLP-1 receptor agonist; the Wegovy label uses that wording.[26]

Is there oral semaglutide?

In a randomized trial of oral semaglutide, mean weight change at 64 weeks was -13.6% against -2.2% on placebo.[6]

What does semaglutide do besides weight loss?

In people with type 2 diabetes and chronic kidney disease, a kidney-outcome trial found a 24% lower risk of a primary-outcome event.[7]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: Approved by FDA as Ozempic (2017), Rybelsus (2019) and Wegovy (2021), semaglutide, Novo Nordisk. Ozempic is indicated for type 2 diabetes; Wegovy for weight reduction and cardiovascular risk reduction (see label quotes). Drugs@FDA also lists a tentatively approved generic semaglutide application (Apotex, 7 Apr 2026).U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  4. 4FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  5. 5Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  6. 6Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
  7. 7Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.The New England journal of medicine · 2024PMID 38785209Accessed 2 Oct 2026
  8. 8Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.Nature medicine · 2025PMID 39455729Accessed 2 Oct 2026
  9. 9Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
  10. 1012-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.EClinicalMedicine · 2024PMID 39764175Accessed 2 Oct 2026
  11. 11Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.The New England journal of medicine · 2024PMID 39476339Accessed 2 Oct 2026
  12. 12Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
  13. 13Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.American heart journal · 2025PMID 40345413Accessed 2 Oct 2026
  14. 14These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: semaglutide[ti] AND (STEP OR "once-weekly semaglutide in adults with overweight or obesity" OR "Semaglutide 2.4 mg") AND randomized controlled trial[pt] (136 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16PubMed search: semaglutide[ti] AND (cardiovascular outcomes OR "SELECT" OR "SUSTAIN" OR "PIONEER 6" OR "myocardial infarction") (560 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17PubMed search: semaglutide[ti] AND (kidney OR FLOW OR "steatohepatitis" OR ESSENCE OR "heart failure" OR "knee osteoarthritis" OR Alzheimer) (590 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18PubMed search: semaglutide[tiab] AND (meta-analysis[pt] OR systematic review[pt]) AND (weight OR obesity OR cardiovascular OR HbA1c) (361 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  19. 19PubMed search: semaglutide[tiab] AND (pharmacokinetic*[tiab] OR half-life[tiab]) AND humans[mh] (136 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  20. 20PubMed search: semaglutide[ti] AND (chronic kidney disease OR "knee osteoarthritis") AND randomized controlled trial[pt] (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  21. 21PubMed search: semaglutide[tiab] AND (depress*[ti] OR suicid*[ti] OR "psychiatric"[ti] OR Alzheimer*[ti] OR cognit*[ti]) (159 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  22. 22PubMed search: semaglutide[tiab] AND (blood pressure[ti] OR lipid*[ti] OR cholesterol[ti] OR "visceral"[ti] OR "waist"[ti] OR "body composition"[ti]) (112 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  23. 23PubMed search: semaglutide[tiab] AND (rheumatoid[tiab] OR "psoriatic"[tiab] OR "inflammation"[ti] OR "C-reactive"[ti]) (60 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  24. 24PubMed search: semaglutide[ti] AND ("knee osteoarthritis" OR "osteoarthritis" OR "obesity-related") AND (pain OR knee) (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  25. 25PubMed search: semaglutide[tiab] AND (Alzheimer*[tiab] OR evoke[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  26. 26WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  27. 27Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
  28. 28Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.The New England journal of medicine · 2023PMID 37952131Accessed 2 Oct 2026
  29. 29A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.Expert opinion on pharmacotherapy · 2024PMID 38629387Accessed 2 Oct 2026
  30. 30The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy.Scientific reports · 2024PMID 39424950Accessed 2 Oct 2026
  31. 31ema.europa.eu pageEuropean Medicines Agency · 2026ema.europa.euAccessed 2 Oct 2026

Found an error? Report a correction.